Hainan Quanxing Pharmaceutical Co. Ltd.

To investigate whether there are differences in the extent and rate of absorption of the test preparation piracetam tablets (Hainan Quanxing Pharmaceutical Co., Ltd., specification: 0.4 g) and the reference preparation piracetam tablets (trade name: Nootropil®; UCB Pharma S.A., specification: 0.8 g) after a single oral administration on an empty stomach or after a meal in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach or after a meal, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

The azithromycin dry suspension (trade name: Xishumei®) certified by Pfizer Pharmaceuticals Co., Ltd. was used as the reference preparation, and the azithromycin dry suspension produced by Hainan Quanxing Pharmaceutical Co., Ltd. was used as the test preparation. The human bioequivalence of the two preparations was evaluated through a single-center, open, randomized, single-dose, three-cycle, three-sequence, partially repeated crossover clinical study. Secondary study purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

To investigate whether there are differences in the extent and rate of absorption between the test preparation alendronate sodium tablets (Hainan Quanxing Pharmaceutical Co., Ltd., specification: 70 mg) and the reference preparation alendronate sodium tablets (trade name: Fosamax ®, MSD PHARMA (SINGAPORE) PTE. LTD., specification: 70 mg) after a single oral administration on an empty stomach in healthy subjects, to evaluate the bioequivalence trend of the test preparation and the reference preparation when administered on an empty stomach, to provide a basis for formal trials, and to observe the safety of the test preparation and the reference preparation in healthy subjects.